{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.5","value":"33.3"},{"groupId":"OG001","spread":"14.1","value":"33.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 1, Day 10 (Venetoclax with LDAC)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.9","value":"51.8"},{"groupId":"OG001","spread":"19.8","value":"35.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 1, Day 18 (Venetoclax Alone)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg (Day 2) and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received low-dose cytarabine (LDAC; 20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.","id":"OG000","title":"Phase 1: 600 mg Venetoclax + LDAC"},{"description":"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 100 mg (Day 2) and increased up to 800 mg by Day 6. Beginning with Cycle 2, 800 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.","id":"OG001","title":"Phase 1: 800 mg Venetoclax + LDAC"}],"paramType":"MEAN","populationDescription":"Participants enrolled in Phase 1 who had at least one dose of venetoclax and had at least one reported PK sample concentration with available data at each time point","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 10 at predose and 2, 4, 6, 8, and 24 hours postdose (venetoclax with LDAC); Cycle 1, Day 18 at predose, 2, 4, 6, 8, and 24 hours postdose (venetoclax alone)","title":"Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax","type":"PRIMARY","unitOfMeasure":"µg*h/mL"}